However, the clinical application of CTLA4 inhibitors in ccRCC is strictly limited, for that the therapeutic response and prognostic value of CTLA4 in ccRCC have not been investigated in detail. The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.